‘Xarelto’ registered for prioritized sales right as generic

The novel oral anticoagulant(NOAC), rivaroxaban(product name: Xarelto, Bayer)’ was registered in the list of pharmaceutical products with prioritized sales product approval for the 41^th times.

SK Chemicals which succeeded in commercializing the first generic(first-developed generic drug) is able to exercise the 9-month prioritized right from October 4, 2021 to July 3, 2022 after the Xarelto’s...